BioProNET recently funded 7 Industrial Biotechnology Seeding Catalyst Award. These awards were designed to accelerate translational research by developing and progressing research along the technology readiness level (TRL) pathway, increasing business—academic engagement and company leverage on innovation activities, as well as generating data to support applications for larger grant funding. Below are the key aims and outcomes from each of these projects.
Download a pdf here
October 10-11th 2018
British Medical Association House, Central London
Thank you to everyone who made this meeting a huge success. Photos will be shared with members once the photos are ready.
Wednesday October 10th
9.30 Registration
10.15-10.30 Welcome, achievements and what next for BioProNET
Designing more efficient cell-expression systems chaired by Mark Smales
10.30-10.55 Kerstin Otte University of Applied Science Biberach, Germany Identification and characterisation of intracellular production bottlenecks in CHO cells producing complex biopharmaceuticals
10.55-11.20 Colin Robinson University of Kent Development of next generation E. coli platforms for the regulated production and periplasmic targeting of biotherapeutics
11.20-11.45 Tarit Mukhopadhyay University College London Manufacturing the future at less than a $1 a dose and meeting global health needs
11.45-11.55 Andrew Peden University of Sheffield Developing a toolkit for determining the manufacturability of new therapeutics in CHO cells
11.55-12.20 Nathan Lewis University of California San Diego, USA Engineering CHO cells with enhanced traits with multiplex genome editing
Building expression systems into optimised process chaired by Yvonne Genzel
13.25-13.50 Gary Finka GlaxoSmithKline Developing a next-generation cell line development platform through targeted automation, analytics and informatics
13.50-14.15 Sophia Hober Royal Institute of Technology, Sweden The human secretome project
14.15-14.25 Mayur Parekh Teesside University Improved preservation of biologics by continuous intensified lyophilisation
14.25-14.35 James Winterburn University of Manchester From bench to business with UKRI funding
14.35–15.00 Natalio Krasnogor Newcastle University Synthetic portabolomics: bridging the gap between the lab bench and industry to speed up the development of new biotech products
The clinic and beyond chaired by Laura Palomares
15.40-16.05 Caroline Barelle Elasmogen soloMERä Biologics: Site-specific therapeutic biologics for the treatment of inflammatory disease
16.05-16.20 Simon Saxby Leaf Expression Systems Plant produced biologics – process economics
16.20-16.30 Michael Plevin University of York Can an archaeal helicase enhance the performance of a nanopore DNA sequencer?
16.30-16.40 Pavlos Kotidis Imperial College London A mathematical model to describe CHO cell growth and monoclonal antibody glycosylation
18.00 Poster session
20.00 Conference dinner
Thursday October 11th
Upstream meets downstream – rapid process development chaired by Cleo Kontoravdi
9.00-9.25 Paul Dalby University College London Analysis and control of protein dynamics and stability: downstream to formulation
9.25-9.50 Yvonne Genzel Max Planck Institute for Dynamics of Complex Technical Systems, Germany Intensified cell-based viral vaccine processes: from continuous to perfusion and to hybrid systems
9.50-10.15 Maiken Kristiansen MedImmune Nucleic acid production for biotherapeutics
10.15-10.25 Dave Brockwell University of Leeds Investigating the effects of hydrodynamic force on the structure and biological integrity of a viral vector gene therapy product
10.25-10.35 Davide Vito University of Kent Translation engineering through the non-coding genome in CHO cells
10.35-11.00 Pernille Harris Technical University of Denmark Solution structure and self-association of pharmaceutical proteins
Molecular characterisation of process quality chaired by Alan Dickson
11.40-12.05 Mike Betenbaugh Johns Hopkins University, USA Glycoengineering of mammalian cell lines to improve product quality
12.05-12.30 Laura Palomares National Autonomous University of Mexico Challenges of bringing recombinant vaccines to the market: A case study for a influenza vaccine
12.30-12.40 Perdita Barran University of Manchester Top-down mass spectrometry methods for full characterisation of biopharmaceuticals
12.40-12.50 Rosa Morra University of Manchester Classical and non-classical secretion pathways in E. coli for periplasmic and extracellular recombinant protein production
12.50-13.15 Jonathan Bones The National Institute for Bioprocessing Research and Training, Ireland Characterisation of biopharmaceuticals using intact protein separations hyphenated to high resolution native mass spectrometry
Using big data and computational methods in bioprocessing
June 11th, University of Kent, Canterbury
9.30am (registration), 10am–5.00pm
The continuing advances in computational methods and the greater use of high throughput omics approaches has increased the potential for greater application of these methods in bioprocessing. This workshop will focus on a number of main areas including: 1) antibody design, 2) use of genetic variation when analysing CHO cells for biologics production 3) protein modelling to investigate properties such as aggregation and binding of host cell impurities to biologics.
Confirmed speakers include Charlotte Deane, University of Oxford, Mark Wass, University of Kent and Nicole Borth, Universität für Bodenkultur, Vienna, Austria.
For more details contact Mark Wass
To register: https://www.surveymonkey.co.uk/r/BioProNET_BigData
Travel: If you are coming by train via London, then Canterbury is less than one hour from London St Pancras. More travel details here https://www.kent.ac.uk/locations/canterbury/directions.html
The promise of genome editing: changing bioprocessing, manufacture and much more
18th June, Bradfield Centre, Cambridge Science Park, 11am–4pm
Confirmed speakers include Nicola McCarthy, Horizon Discovery; Mark Fife, Pirbright Institute; Lorenz Mayr, GE Healthcare and Claus Kristensen, University of Copenhagen.
Evolution is so ‘yesterday’ as we enter the revolution offered by genome editing. You may find this opinion provocative but if the cellular systems we have are not good enough for the functions needed, why should we not just build new ones by changing the genetic makeup of the cell, So far, so good… the promise remains but what is the reality of this hope? In this workshop we are bringing together expert opinion leaders from academia and industry to examine the likelihood of the expectations being translated to outcomes. Via short expert presentations and focused group discussions, the participants will examine how the potential of genome editing to change the manufacture of bio-based products may be enhanced and the practical consequences of such interventions from a commercial perspective.
Registration link and more information: http://app1.horizondiscovery.com/biopronet-2018-event-application
Bioprocess Intensification
July 4th, University College London 9.30am–5.30pm
The continued growth of the biopharmaceutical industry is being challenged by a greater number and variety of products than in the past. The industry is also increasingly concerned with the affordability of these products. These key factors means process intensification has become a critical objective. The goal is higher productivity processes to enable small process trains, resulting in cost-effective, lean, and agile manufacturing facilities. The symposium assembles 8 leaders from the biopharmaceutical industry and academia (Line Lundsberg-Nielsen (NNE), Hani El-Sabbahy (3M/UCL), Ajoy Velayudhan (UCL) Peter Levison (Pall), Will Lewis (GSK), Jonathan Souquet (Merck KGaA), John Welsh (Pall) Suzy Farid (UCL)) who will present their latest findings and opinions on the subject. By bringing together scientists and engineers from academia and industry who are actively engaged in bioprocess intensification the event will provide forum for lively debate.
Registration here: https://www.surveymonkey.co.uk/r/BioProNET_BioprocessIntensification
The programme is available here
Directions: https://www.ucl.ac.uk/maps/jz-young-lt
Conratulations to the winners of the poster and short talk prizes at our 4th annual science meeting, who received their prizes from Karen Lewis of the BBSRC (far left).
The winners were Rochelle Aw, Imperial College London – 1st prize talk (pictured 2nd left); Eva Pekle, MedImmune & Univserity of Kent – 2nd prize talk (pictured middle); Tania Selas Castiñeiras, Cobra Biologics – 3rd talk prize; Hirra Hussain, University of Manchester – 1st prize poster, Natalie Talbot, University of Kent – 2nd prize poster (pictured 2nd right) and James Budge, University of Kent – 3rd poster prize (pictured far right).
BioProNET has recently awarded six indistrial biotecnology seeding catalyst awards (IBSCA). This funding aims to develop and progress ideas and technology within the scope and remit of BioProNET and the call along the technology readiness level (TRL) pathway.
Pilot production of engineered nucleases with applications in molecular biology and diagnostic devices
Jon Sayers, University of Sheffield
Optimization of influenza vaccine manufacturing through inhibition of autophagy
Jeremy Rossman, University of Kent
Improved microfluidic devices for downstream bioprocess separation of sub-micron targets
Alan Goddard, Aston University
Learning from charge interactions in nature to understand poly-anion/cation complementarity in drug encapsulation
Jim Warwicker, University of Manchester
Engineering secretory capacity in S. cerevisiae strains to improve recombinant protein production yield
Campbell Gourley, University of Kent
Enhancing secretory pathway function to allow selection of host cell clones
Lisa Swanton, University of Manchester
Establishing a prototype process for manufacturing non‐therapeutic biologics expressed in plants for the R&D market
Anil Day, University of Manchester
